Memorial Sloan Kettering Cancer Center

New York University

Fundacion Para El Fomento De La Investigacion Sanitaria Y Biomedica De La Comunitat Valenciana (Fisabio)

Eric G Pamer

Peter McKenney

Silvia Caballero

Sohn Kim

Dan R Littman

Steven B Abramson

Carles Ubeda

Jose U Scher

Charlie Buffie

Jedd David Wolchok

Marcel Van Den Brink

Randy S Longman

Melody Smith

Eric Littmann

Simone Becattini

Sergei B Koralov

Krista Dubin

Andrew Sczesnak

Robert Jenq

Yusuke Shono

Ying Taur

The present invention relates to methods and compositions for reducing the risk and severity ofinfection. It is based, at least in part, on the discovery that a restricted fraction of the gut microbiota, including the bacterium, contributes substantially to resistance againstinfection. Without being bound by any particular theory, it is believed that this is achieved through the biosynthesis of secondary bile acids.

Methods and compositions for reducing clostridium difficile infection

The present disclosure relates to novel lantibiotics, lantibiotic pharmaceutical compositions, isolated and recombinant lantibiotic-producing bacteria, bacterial pharmaceutical compositions, methods of producing novel lantibiotics from lantibiotic-producing bacteria, and methods of using such lantibiotics, lantibiotic pharmaceutical compositions, and bacterial pharmaceutical compositions to treat gram-positive bacteria infections, including vancomycin resistant enterococci infections, in patients, and to treat food and other objects to avoid gram-positive bacteria contamination.

Lantibiotics, lantibiotic-producing bacteria, compositions and methods of production and use thereof

The present invention relates to compositions, methods, and kits for predicting a subject's response to a CAR T cell therapy, by analyzing the intestinal microbiome of the subject. The present disclosure also provides a method of detecting patients at risk for a poor response to CAR T cell therapy by measuring the level of the presently disclosed bacteria or bacterial genes in the microflora or microbiome of a patient receiving or considered for CAR T cell therapy. The present disclosure further provides therapeutic compositions and methods for treating a subject having a cancer, by improving the subject's response to a CAR T cell therapy.

Methods and compositions for identifying and treating subjects at risk for poor CAR T cell therapy response

Methods and compositions for reducinginfection

The disclosure relates to a therapeutic composition for treatinginfection orcolonization, the composition including at least one, at least two, at least three, or all of an isolatedbacteria, an isolatedbacteria, an isolatedbacteria, and/or an isolatedbacteria in a formulation suitable for administration to a subject. The disclosure further provides similar compositions lacking an isolatedbacteria. The disclosure additionally provides methods of treatinginfection or colonization using such compositions.

Methods and compositions for reducinginfection or colonization

The present invention relates to methods and compositions for reducing the risk and severity of vancomycin-resistantinfection or colonization. It is based, at least in part, on the discovery that a restricted fraction of the gut microbiota, including the bacteriaand/or the bacteriacontribute substantially to resistance against vancomycin-resistantinfection or colonization. Without being bound by any particular theory, it is believed that this is achieved through the biosynthesis of secondary bile acids in the case of

Methods and compositions for reducing vancomycin-resistant enterococci infection or colonization

The present invention relates to methods and compositions for identifying subjects treated with or considered for treatment with checkpoint blockade therapeutic agents that are at higher or lower risk for developing checkpoint therapy associated colitis, by analyzing the intestinal microbiome of those subjects. It is based, at least in part, on the discovery that the abundance of certain intestinal microbiota of the phyla Bacteroidetes, including the bacteria in the families Bacteroidaceae, Rikenellaceae, and Barnesisllaceae, and/or an increase or decrease in microbial genetic pathways involved in polyamine transport and/or B vitamin biosynthesis (e.g., (riboflavin (B2), pantothenate (B5) and thiamine (B1)) are associated with the likelihood of developing checkpoint therapy associated colitis.

Methods and compositions for identifying and treating subjects at risk for checkpoint blockade therapy associated colitis

The present invention relates to methods and compositions for reducing the risk and severity of vancomycin-resistant Enterococci infection or colonization. It is based, at least in part, on the discovery that a restricted fraction of the gut microbiota, including the bacteriaand/or the bacteriacontribute substantially to resistance against vancomycin-resistant Enterococci infection or colonization. Without being bound by any particular theory, it is believed that this is achieved through the biosynthesis of secondary bile acids in the case of

Methods and compositions for reducing vancomycin-resistantinfection or colonization

Methods, agents and compositions thereof for treating psoriatic arthritis (PsA) are encompassed herein.

Methods for treating psoriatic arthritis

Methods, reagents and compositions thereof for predicting RA onset in susceptible individuals, diagnosing RA onset, and/or evaluating efficacy of a therapeutic regimen for treating RA are described herein. Determining the amount of a particular bacterial species comprising SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3 (SEQ ID NO: 1+ bacteria) serves as a biomarker for the above indications.

Growing community of inventors

Guilford, CT, United States of America

Eric G Pamer